CRESCENDO
LIVE

Serial Number

79331946

Owner

Crescendo Biologics Limited

Attorney

Matthew L. Frisbee

Filing Date

Aug 12, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CRESCENDO Trademark

Serial Number: 79331946 • Registration: 6915016

CRESCENDO is a trademark filed by Crescendo Biologics Limited on August 12, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 31 (Natural Agricultural Products). The application is currently registered and active.

Owner Contact Info

Crescendo Biologics Limited (6 trademarks)

Meditrina Building,

Entity Type: 99

Trademark Details

Filing Date

August 12, 2021

Registration Date

December 6, 2022

Published for Opposition

September 20, 2022

Goods & Services

Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; therapeutic preparations that use monoclonal antibodies, namely therapeutic pharmaceutical for treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in the discovery, preclinical and clinical development of therapeutic products for medical and veterinary purposes; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in oncology and therapeutic treatments in relation thereto; pharmaceutical preparations for use in oncology

Live animals; live mice

Chemicals for use in science and industry, namely, chemicals for laboratory research purposes; chemicals for use in science and industry, namely, chemicals for use in medical research; chemicals for use in science and industry, namely, chemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicals, namely, antibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical development, clinical development and manufacture of therapeutic products; chemicals used in industry and science

Scientific and technological services, namely, research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; scientific and technological services, namely, provision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicals, biologicals, antibodies and antibody fragments; scientific services, namely, discovery, preclinical and clinical development of therapeutic products; scientific research for others in the field of drug discovery, preclinical and clinical development of therapeutic and diagnostic products; oncological research; engineering of antibodies and antibody fragments; research into antibodies, antibody fragments for others; research into the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments for others; consultancy, advice and information relating to all of the aforesaid services

Custom manufacture of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragments, for others, for use in medical therapies, including in relation to oncology; consultancy, advice and information relating to all of the aforesaid services

Licensing of intellectual property, namely, licensing of research and development; licensing of intellectual property, namely, licensing of medical therapeutic research; licensing of intellectual property, namely, licensing of research relating to antibodies and antibody fragments; licensing of intellectual property, namely, licensing of research in relation to the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments; consultancy, advice and information relating to all of the aforesaid services

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 14, 2026 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 17, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 17, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 17, 2025 REAP
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jun 3, 2025 LIMN
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Nov 8, 2024 RHRD
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 27, 2023 LIMN
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Aug 19, 2023 RHRD
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 19, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 29, 2023 FICS
FINAL DISPOSITION PROCESSED
Mar 28, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 6, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 6, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 6, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Sep 27, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 20, 2022 NPUB
PUBLISHED FOR OPPOSITION
Sep 20, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 7, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 7, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 31, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 15, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 11, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 11, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 11, 2022 TROA
REFUSAL PROCESSED BY IB
Jul 13, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 16, 2022 RFCS
REFUSAL PROCESSED BY MPU
Jun 16, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 24, 2022 RFCR
NON-FINAL ACTION WRITTEN
May 23, 2022 CNRT
ASSIGNED TO EXAMINER
May 13, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 2, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 29, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 27, 2022 REPR